Three things to know:
1. The Ottawa, Canada-based company is in the pre-clinical stage of developing a biomaterial that uses plant-derived cellulose to generate “scaffold architectures” for regenerative medicine.
2. Spiderwort’s biomaterials demonstrated promise for the treatment of spinal cord injuries and soft tissue regeneration in pre-clinical trials.
3. The company, which recently moved into a biotechnology research facility in Ottawa, plans to use the funding to reach clinical trials.
More articles on biologics:
How Dr. Vladimir Sinkov opened his solo spine practice in the midst of the COVID-19 pandemic
Steadman Clinic moves to absorb hospital orthopedic group — 6 things to know
Michigan group to open 7th location, add 2 orthopedic surgeons
